Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.47 USD

55.47
1,156,600

+1.15 (2.12%)

Updated Nov 4, 2024 10:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol-Myers' Opdivo Study Meets Early Success, Stock Up

by Zacks Equity Research

Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.

    Arpita Dutt headshot

    Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018

    by Arpita Dutt

    Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.

      Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold

      by Zacks Equity Research

      Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma.

        AbbVie Submits NDA for Endometriosis Candidate to the FDA

        by Zacks Equity Research

        AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

          4 Drug Stocks Worth a Look on Promising Cancer Pipeline

          by Zacks Equity Research

          Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

            Arpita Dutt headshot

            Key FDA Regulatory Events to Watch Out for in Sep 2017

            by Arpita Dutt

            Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?

              Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

              by Zacks Equity Research

              Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.

                Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe

                by Zacks Equity Research

                Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.

                  Pfizer Presents Encouraging Eliquis Results in NVAF Patients

                  by Zacks Equity Research

                  Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

                    by Arpita Dutt

                    It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

                      Celldex Ends Phase II Enrollment for Breast Cancer Candidate

                      by Zacks Equity Research

                      Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

                        Here's Why Clovis Stock Is Up Almost 60% So Far in 2017

                        by Zacks Equity Research

                        Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

                          Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

                          by Zacks Equity Research

                          Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo

                            by Arpita Dutt

                            Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.

                              Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

                              by Zacks Equity Research

                              Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

                                FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

                                by Zacks Equity Research

                                FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

                                  Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

                                  by Zacks Equity Research

                                  Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

                                    Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

                                    by Zacks Equity Research

                                    Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

                                      Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

                                      by Zacks Equity Research

                                      Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

                                        Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

                                        by Zacks Equity Research

                                        Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure

                                          by Arpita Dutt

                                          This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.

                                            AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

                                            by Zacks Equity Research

                                            AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

                                              Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up

                                              by Zacks Equity Research

                                              Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                                                Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View

                                                by Zacks Equity Research

                                                Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.

                                                  Sweta Killa headshot

                                                  Q2 Earnings Fail to Impress Pharma ETF

                                                  by Sweta Killa

                                                  The string of earnings beat failed to boost pharma ETFs.